FDA Proposes Exclusion of Key Weight-Loss Drugs

The FDA has proposed to exclude weight-loss drugs semaglutide, tirzepatide, and liraglutide from its 503B bulks list, which would limit their compounding unless they appear on the agency's drug shortage list. This decision could have significant implications for the availability of these popular medications.

The U.S. Food and Drug Administration has taken a significant step by proposing the exclusion of weight-loss drugs semaglutide, tirzepatide, and liraglutide from its 503B bulks list.

This move is poised to restrict the compounding of these medications, making them less accessible unless they are listed on the agency's drug shortage list.

The decision could potentially impact patients relying on these treatments for weight management and call for adjustments in how these medications are accessed and prescribed.